Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Calculus Bovis Sativus in MAFLD
NCT07085962Not yet recruiting
- Sponsor
- Huazhong University of Science and Technology
- Start
- Aug 2025
- Primary completion
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial in metabolic dysfunction associated fatty liver disease (MAFLD) comparing Calculus bovis sativus group with Placebo group (2 arms). Primary endpoint: Change from Baseline in Alanine Aminotransferase at 12 weeks. Planned start Aug 2025; status: not yet recruiting.
02
Drugs
calculus bovis sativus
03
Conditions
metabolic dysfunction associated fatty liver disease (MAFLD)
Beyond the preview
Go deeper on NCT07085962.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07085962.